Jakob Dupont - Mar 2, 2023 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
EVP, Head of R&D
Signature
/s/ Jeff Kiekhofer, Attorney-in-Fact for Jakob Dupont
Stock symbol
ATRA
Transactions as of
Mar 2, 2023
Transactions value $
-$18,403
Form type
4
Date filed
3/6/2023, 05:46 PM
Previous filing
Mar 3, 2023
Next filing
Aug 25, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Sale -$18.4K -5.07K -1.71% $3.63 291K Mar 2, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
F2 The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on March 2, 2023 and March 3, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.